A Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

About this Study

The purpose of this study is to determine if receiving the study drug pembrolizumab before and after surgery or only at surgery is better, the same or worse than usual treatment after surgery.

Sponsor Protocol ID:S1801
IRB Number:2019-0023
Actively Enrolling
Interventional
Phase 2
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities, but was not designed to measure differences of intervention effects.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Wilkinson, Kelly J, M.D.
How to participate in our Clinical Trials